# Study on Efficacy and Safety of Reparixin in the Treatment of Hospitalized Patients With Severe COVID-19 Pneumonia.

> **NCT04878055** · PHASE3 · COMPLETED · sponsor: **Dompé Farmaceutici S.p.A** · enrollment: 287 (actual)

## Conditions studied

- Pneumonia, Viral

## Interventions

- **DRUG:** Reparixin
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04878055
- **Lead sponsor:** Dompé Farmaceutici S.p.A
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-02-14
- **Primary completion:** 2021-09-30
- **Final completion:** 2021-10-31
- **Target enrollment:** 287 (ACTUAL)
- **Last updated:** 2024-06-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04878055

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04878055, "Study on Efficacy and Safety of Reparixin in the Treatment of Hospitalized Patients With Severe COVID-19 Pneumonia.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04878055. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*